Advertisement
U.S. markets close in 1 hour 11 minutes
  • S&P 500

    5,252.60
    +4.11 (+0.08%)
     
  • Dow 30

    39,774.15
    +14.07 (+0.04%)
     
  • Nasdaq

    16,380.21
    -19.31 (-0.12%)
     
  • Russell 2000

    2,123.28
    +8.93 (+0.42%)
     
  • Crude Oil

    83.07
    +1.72 (+2.11%)
     
  • Gold

    2,240.00
    +27.30 (+1.23%)
     
  • Silver

    24.94
    +0.19 (+0.78%)
     
  • EUR/USD

    1.0793
    -0.0036 (-0.33%)
     
  • 10-Yr Bond

    4.2060
    +0.0100 (+0.24%)
     
  • dólar/libra

    1.2619
    -0.0019 (-0.15%)
     
  • USD/JPY

    151.3850
    +0.1390 (+0.09%)
     
  • Bitcoin USD

    70,557.59
    +1,790.98 (+2.60%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,952.62
    +20.64 (+0.26%)
     
  • Nikkei 225

    40,168.07
    -594.66 (-1.46%)
     

CITIC Capital offers to buy China Biologic for $110 per share

(Adds details on transaction, background, share price)

June 18 (Reuters) - A unit of Chinese investment firm CITIC Capital Holdings Ltd said on Monday it has offered to buy U.S.-listed biotech firm China Biologic Products Holdings Inc , in a deal valuing the company at $3.65 billion.

China Biologic makes and sells plasma products, such as human immunoglobin, to prevent diseases such as measles and hepatitis.

The company's shares rose 15.8 percent to $95 in premarket trading.

The unit, CCRE, offered $110 in cash for each share of China Biologic it does not already own. (https://bit.ly/2leBZGo)

As of June 8, CCRE owned a 5.1 percent stake in China Biologic.

CCRE said it plans to finance the transaction with a combination of debt and equity. (Reporting by Manas Mishra in Bengaluru; Editing by Sai Sachin Ravikumar and Shounak Dasgupta)

Advertisement